Search clinical trials for: Degarelix

Total 152 results

Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Prostate Cancer

United States
Mark Stein
Regeneron Pharmaceuticals

Active, not recruiting

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Prostate Cancer Metastatic

United States
Jonsson Comprehensive Cancer Center
GlaxoSmithKline; Novartis; Astellas Pharma Inc; Prostate Cancer Foundation; Medivation...

Active, not recruiting

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals; University of Michigan; University of Texas Southwestern...

Completed

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Metastatic Castration Sensitive Prostate Cancer

United States
Al-Rasheed University College

Completed

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Polycystic Ovary Syndrome

Iraq
Brigham and Women's Hospital

Completed

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

Prostate Cancer

United States
Alliance Foundation Trials, LLC.
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer (PandaExtension)

Prostate Cancer

China
Columbia University
Bristol-Myers Squibb; Ferring Pharmaceuticals

Active, not recruiting

Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer (Neo-Red-P)

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

FIRMAGON Intensive Drug Monitoring Protocol

Prostate Cancer

China
Nova Scotia Health Authority
Dalhousie University

Completed

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Cancer

Canada
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer (DEGASTIM)

Invasive Ductal Breast Carcinoma

France
Ferring Pharmaceuticals
Memorial Sloan Kettering Cancer Center; Duke Clinical Research Institute

Terminated

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE)

Prostate Cancer

United States, France, Canada, Czechia, Finland, Germany, Greece, Poland, Russian Federation, Slovakia, South Africa, United Kingdom
VA Office of Research and Development

Completed

Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH)

COVID-19

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.

Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Secondary Hyperparathyroidism

China, Hong Kong, Korea, Republic of, Taiwan
University of Washington
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Completed

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7

United States
Ferring Pharmaceuticals

Completed

A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer

Prostate Cancer

India
Memorial Sloan Kettering Cancer Center
University of California, Los Angeles; Ferring Pharmaceuticals; Wayne State University and other collaborators

Completed

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer

Stage IV Prostate Cancer

United States
Bayer

Completed

Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases (PARABO)

Castration-Resistant Prostatic Cancer

Germany
M.D. Anderson Cancer Center
Bayer

Completed

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

Breast Cancer

United States
University of Colorado, Denver

Completed

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

Cognitive Impairment | Menopause | Endothelial Dysfunction | Vascular Stiffness | Estrogen Deficiency

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
Universitaire Ziekenhuizen KU Leuven

Unknown

Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO)

Prostate Cancer | Neoadjuvant Therapy | Prostatectomy | Androgen Antagonists

Belgium
Assisting Nature

Unknown

Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Infertility | Premature Ovarian Failure

Greece
Assisting Nature

Unknown

Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix

Pregnancy, Ovarian

Greece
Ottawa Hospital Research Institute

Terminated

A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (OTT10-06)

Prostatic Neoplasms

Canada
United Clinic Management GmbH

Completed

Treatment of Prostate Cancer With Firmagon®

Prostate Cancer

Germany
British Columbia Cancer Agency

Completed

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Prostate Cancer

Canada
Lund University
Swedish Cancer Foundation; ALF Swedish Government Grant

Completed

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Prostate Cancer Recurrent

Sweden
Rabin Medical Center
Ferring Pharmaceuticals

Unknown

Cardiovascular Events in GnRH Agonist vs. Antagonist

Prostate Cancer | Cardiac Event | Hormone Sensitive Prostate Cancer

Israel
Canadian Urology Research Consortium
Ferring Pharmaceuticals

Terminated

Firmagon (Degarelix) Intermittent Therapy (FIT)

Prostate Cancer Recurrent

Canada
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy (CaNCaP03)

Prostate Cancer

United Kingdom
Bayer

Completed

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Prostatic Neoplasms

United States
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany
Ferring Pharmaceuticals

Completed

Safety and Efficacy of Firmagon® (Degarelix) for Injection

Prostate Cancer

Korea, Republic of
Rabin Medical Center
Ferring Pharmaceuticals

Completed

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

Cardiovascular Diseases | Prostatic Neoplasms

Israel
Mayo Clinic

Completed

Impact of Estradiol Addback

Normal Healthy Volunteers

United States
Astellas Pharma Inc

Completed

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Prostatic Neoplasms

Japan
Astellas Pharma Inc

Completed

A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer

Prostate Cancer

Japan
ETOP IBCSG Partners Foundation

Completed

TRial on the Endocrine Activity of Neoadjuvant Degarelix (TREND)

Breast Cancer Invasive Nos

Italy
Sidney Kimmel Comprehensive Cancer Center at Johns...
BioSante Pharmaceuticals; David H. Koch Charitable Foundation

Completed

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

Prostate Cancer Adenocarcinoma in Situ

United States
Ferring Pharmaceuticals

Completed

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)

Prostate Cancer

France
University of Washington
National Cancer Institute (NCI)

Completed

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
The University of Texas Health Science Center,...

Terminated

Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer

Prostatic Neoplasms

United States
The University of Texas Health Science Center,...

Terminated

Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer

Prostate Cancer

United States
Ferring Pharmaceuticals

Completed

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina (FAST AR)

Advanced Hormone Dependent Prostate Cancer

Argentina

Search clinical trials for: Degarelix

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations